Obesity and healthcare resource utilization: results from Clinical Practice Research Database (CPRD)
C W. le Roux B. ChubbE. Nørtoft A. Borglykke
Acknowledgements: The study was funded by Novo Nordisk. We thank Christiane Lundegaard Haase of Novo Nordisk, for review comments, and Jamie Cozens, MSc, of Watermeadow Medical, an Ashfield Company, for editorial and medical writing services, which were funded by Novo Nordisk.
Declaration of interest: CWlR has been an advisory board member for Fractyl, Herbalife, GI Dynamics, and Novo Nordisk, and has received speaker’s fees from Boehringer Ingelheim, Janssen, Johnson & Johnson, Medtronic, and Sanofi. EN, BC and AB are employees of Novo Nordisk. BC is additionally a shareholder at Novo Nordisk.
Funding: Novo Nordisk, Denmark
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/osp4.291
Summary
Background/Objectives
The economic burden of obesity and type 2 diabetes (T2D) rises with increasing prevalence. This study estimates the association between obesity, healthcare‐resource utilization (HCRU) and associated costs in individuals with/without T2D.
Subjects/Methods
This observational cohort study used the United Kingdom (UK) Clinical Practice Research Datalink (CPRD) data. Between 01 January 2011 and 31 December 2015 total HCRU costs and individual component costs (hospitalizations, GP contacts, prescriptions) were calculated for individuals linked to the Hospital Episodes Statistics database with/without T2D with normal weight, overweight, class I, II, III obesity.
Results
396,091 individuals were included. Increasing BMI was associated with increased HCRU costs. At each BMI category costs were greater for individuals with than without T2D. Relative to normal BMI, increasing BMI was positively associated with increased HCRU costs, with similar magnitude regardless of T2D. The total HCRU cost for an individual with class III obesity was 1.4‐fold (£3695) greater than for normal weight.
Conclusion
In the UK, HCRU costs were positively associated with increasing BMI, irrespective of T2D status. The combination of T2D and obesity was associated with higher HCRU costs compared with individuals of the same BMI, without T2D. These findings suggest that prioritizing weight management programmes focused specifically on individuals with obesity and T2D may be more cost‐effective than for those with obesity alone.
Full Publication Here